Author: Dorian Fitzwilliam - Page 2

20Mar

FDA Authorization of Generics: Legal Basis and Approval Process

Posted by Dorian Fitzwilliam 15 Comments

The FDA approves generic drugs through the Hatch-Waxman Act and ANDA pathway, ensuring they match brand-name drugs in safety, strength, and effectiveness. Over 90% of U.S. prescriptions are filled with generics, saving billions annually.

14Mar

Accidental Pediatric Medication Overdose: How to Prevent It and What to Do If It Happens

Posted by Dorian Fitzwilliam 15 Comments

Accidental pediatric medication overdoses are common but preventable. Learn how child-resistant packaging, dosing errors, and unsafe storage put kids at risk-and what real steps parents can take to protect them.

8Mar

MAOI Dietary Restrictions: Tyramine Triggers and Safety Plan

Posted by Dorian Fitzwilliam 13 Comments

MAOI antidepressants require strict dietary restrictions to avoid tyramine-triggered hypertensive crises. Learn which foods are truly risky, how modern food science changes old rules, and how to build a personalized safety plan.

6Mar

How to Read OTC Drug Facts Labels Correctly and Confidently

Posted by Dorian Fitzwilliam 10 Comments

Learn how to read OTC drug facts labels step by step to avoid dangerous mistakes, double dosing, and hidden allergies. The FDA's standardized label saves lives - if you know how to use it.

1Mar

Supply Chain Problems: How Distribution Risks Are Leaving Patients Without Generic Drugs

Posted by Dorian Fitzwilliam 12 Comments

Generic drugs make up 90% of U.S. prescriptions but are disappearing due to fragile global supply chains, low profit margins, and manufacturing concentration in China and India. Millions of patients are at risk.

28Feb

How to Use a Medication Action Plan Template During Healthcare Visits

Posted by Dorian Fitzwilliam 9 Comments

Learn how to use a Medication Action Plan template during healthcare visits to reduce errors, improve adherence, and prevent dangerous drug interactions. A simple tool that saves lives.

27Feb

REMS for Clozapine: What Changed in 2025 and How ANC Monitoring Works Now

Posted by Dorian Fitzwilliam 13 Comments

The FDA removed the mandatory REMS program for clozapine in February 2025. ANC monitoring is still recommended, but no longer tracked by federal systems. Learn how this change improves access and what patients and providers must do now.

22Feb

ACA Plans and Generic Coverage: What You Really Get Under the Affordable Care Act

Posted by Dorian Fitzwilliam 14 Comments

Understand what ACA plans really cover, how subsidies work, and what changes are coming in 2026. Learn how income, metal tiers, and policy shifts affect your premiums and out-of-pocket costs.

21Feb

Immunosuppressants: Cyclosporine and Tacrolimus Generic Issues

Posted by Dorian Fitzwilliam 8 Comments

Cyclosporine and tacrolimus are critical for transplant patients, but generic versions can cause dangerous fluctuations in drug levels. Learn why switching generics isn't safe without careful monitoring and how to protect your transplant.

15Feb

Extended-Release vs. Immediate-Release Medications: Timing, Risks, and What You Need to Know

Posted by Dorian Fitzwilliam 10 Comments

Extended-release and immediate-release medications work differently, affecting how fast they act, how long they last, and their risks. Understanding the difference can prevent overdose, improve effectiveness, and save money.